Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mi-Ran Yun

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2022
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCSeung Yeon Oh, You Won Lee, Eun Ji Lee, et al.
Cell Reports. Medicine|January 28, 2025
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLCSeung Yeon Oh, Sewon Park, Seoyoung Lee, et al.
Molecular Cancer Therapeutics|May 20, 2016
EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell LinesSung-Moo Kim, Hwan Kim, Kang Won Jang, et al.
Scientific Reports|December 29, 2019
Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung AdenocarcinomaSeok-Young Kim, Ji Yeon Lee, Dong Hwi Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung AdenocarcinomaSeok-Young Kim, Sang-Min Kim, Sumin Lim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 13, 2016
Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung CancerKyoung Ho Pyo, Sun Min Lim, Hye Ryun Kim, et al.
Experimental & Molecular Medicine|August 23, 2022
DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapyHaejeong Heo, Jong-Hwan Kim, Hyun Jung Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2024
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLCEun Ji Lee, Seung Yeon Oh, You Won Lee, et al.
Molecular Cancer Therapeutics|July 26, 2015
Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung AdenocarcinomaChan Woo Kang, Kang Won Jang, Jinyoung Sohn, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer modelsHan Na Kang, Se-Ho Kim, Mi Ran Yun, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2022
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCSeung Yeon Oh, You Won Lee, Eun Ji Lee, et al.
Cell Reports. Medicine|January 28, 2025
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLCSeung Yeon Oh, Sewon Park, Seoyoung Lee, et al.
Molecular Cancer Therapeutics|May 20, 2016
EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell LinesSung-Moo Kim, Hwan Kim, Kang Won Jang, et al.
Scientific Reports|December 29, 2019
Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung AdenocarcinomaSeok-Young Kim, Ji Yeon Lee, Dong Hwi Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung AdenocarcinomaSeok-Young Kim, Sang-Min Kim, Sumin Lim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 13, 2016
Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung CancerKyoung Ho Pyo, Sun Min Lim, Hye Ryun Kim, et al.
Experimental & Molecular Medicine|August 23, 2022
DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapyHaejeong Heo, Jong-Hwan Kim, Hyun Jung Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2024
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLCEun Ji Lee, Seung Yeon Oh, You Won Lee, et al.
Molecular Cancer Therapeutics|July 26, 2015
Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung AdenocarcinomaChan Woo Kang, Kang Won Jang, Jinyoung Sohn, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer modelsHan Na Kang, Se-Ho Kim, Mi Ran Yun, et al.
Pageof 7